CADTH highlights PolypDx™ in their most recent Health Technology Update for Canadian Decision-Makers

CADTH (the Canadian Agency for Drugs and Technologies in Health) introduced PolypDx™ in their latest issue on new and emerging health care technologies in Canada. CADTH is a not-for-profit organization established by the federal, provincial, and territorial governments provides objective evidence to Canada’s health care decision-makers about the optimal use of drugs and medical devices. It is one of the world’s leading health technology assessment (HTA) organizations and an essential contributor to evidence-informed decision-making in Canada. Canadian decision-makers use CADTH’s reports as guidelines with evidence, analysis, advice, and recommendations to make informed decisions.

In the Health Technology Update (Issue 23-March 2019 - “A Urine-Based Metabolomic Test for Colorectal Cancer Screening”), PolypDx™is noted to have the potential to increase access to screening, and notes that urine samples can be easily collected. From the PolypDx™ development to current practice, the report introduced integrated and specialized(professional) information of the test. The results of Canadian Assessment of PolypDx™ (CAP) project now underway in Alberta, will be assessed by a national working group that consists of key provincial and national leaders in colorectal cancer (CRC) screening.

Read the full report on CADTH